CIK 0002023658 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Bicara Therapeutics Inc.
Sign in to watch- Ticker
- BCAX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-468-4219
- Business address
- 116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $400,716
- in 1 filing, $401K under 10b5-1 plans
Net −$400,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-09 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −536 | $29.00 | $16K | 181,641 |
| 2026-07-08 | Cohlhepp Ryan President and COO | Option exercise 10b5-1 | +18,750 | $3.79 | $71K | 210,391 |
| 2026-07-08 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −22,833 | $28.76 | $657K | 187,558 |
| 2026-07-08 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −4,306 | $29.80 | $128K | 183,252 |
| 2026-07-08 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −1,075 | $30.35 | $33K | 182,177 |
| 2026-07-08 | Cohlhepp Ryan President and COO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −18,750 | 70,502 | ||
| 2026-07-08 | Hyep Ivan Chief Financial Officer | Option exercise 10b5-1 | +12,500 | $3.79 | $47K | 157,855 |
| 2026-07-08 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −22,757 | $28.60 | $651K | 135,098 |
| 2026-07-08 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −4,413 | $29.82 | $132K | 130,685 |
| 2026-07-08 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −830 | $30.31 | $25K | 129,855 |
| 2026-07-08 | Hyep Ivan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −11,592 | 58,992 | ||
| 2026-07-08 | Hyep Ivan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −908 | 38,836 | ||
| 2026-06-09 | Bowden Christopher Director | Grant or award · Stock Option (Right to Buy) | +19,475 | 19,475 | ||
| 2026-06-09 | Haviland Kate Director | Grant or award · Stock Option (Right to Buy) | +19,475 | 19,475 | ||
| 2026-06-09 | Mazumdar-Shaw Kiran Director | Grant or award · Stock Option (Right to Buy) | +19,475 | 19,475 | ||
| 2026-06-09 | Robertson Scott M. Director | Grant or award · Stock Option (Right to Buy) | +19,475 | 19,475 | ||
| 2026-06-09 | POWELL MICHAEL Director | Grant or award · Stock Option (Right to Buy) | +19,475 | 19,475 | ||
| 2026-06-09 | Simson Jake Director | Grant or award · Stock Option (Right to Buy) | +19,475 | 19,475 | ||
| 2026-06-09 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award · Stock Option (Right to Buy) | +19,475 | 19,475 | ||
| 2026-05-21 | Hyep Ivan Chief Financial Officer | Option exercise 10b5-1 | +9,200 | $3.79 | $35K | 154,555 |
Page 2 of 14 · 276 trades